Tocqueville Asset Management’s Pacira BioSciences PCRX Stock Holding History

Tocqueville Asset Management’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-5,000	Closed	-$303K	–	742
2021 Q2	$303K	Sell	5,000 -10	-0.2%	-$633	﹤0.01%	634
2021 Q1	$351K	Hold	5,010	–	–	0.01%	610
2020 Q4	$300K	Sell	5,010 -7	-0.1%	-$410	0.01%	623
2020 Q3	$302K	Buy	5,017 +17	+0.3%	+$988	0.01%	566
2020 Q2	$262K	Buy	+5,000	New	+$209K	0.01%	587
2019 Q3	–	Sell	-4,900	Closed	-$213K	–	778
2019 Q2	$213K	Sell	4,900 -2,000	-29%	-$84.9K	﹤0.01%	736
2019 Q1	$263K	Sell	6,900 -1,100	-14%	-$42.9K	﹤0.01%	694
2018 Q4	$344K	Sell	8,000 -2,000	-20%	-$93.4K	0.01%	610
2018 Q3	$492K	Buy	+10,000	New	+$432K	0.01%	625
2016 Q4	–	Sell	-15,200	Closed	-$520K	–	842
2016 Q3	$520K	Hold	15,200	–	–	0.01%	623
2016 Q2	$513K	Hold	15,200	–	–	0.01%	630
2016 Q1	$805K	Buy	15,200 +3,300	+28%	+$193K	0.01%	535
2015 Q4	$914K	Buy	+11,900	New	+$674K	0.01%	559
2015 Q3	–	Sell	-12,750	Closed	-$902K	–	997
2015 Q2	$902K	Sell	12,750 -2,530	-17%	-$199K	0.01%	589
2015 Q1	$1.36M	Buy	15,280 +1,780	+13%	+$181K	0.02%	535
2014 Q4	$1.2M	Buy	+13,500	New	+$1.28M	0.01%	548

Other funds holding PCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return

SCM

Spyglass Capital Management San Francisco, California $1.85B AUM 15.7% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Tocqueville Asset Management's PCRX Position: Q3 2021 in Review

Tocqueville Asset Management sold out of Pacira BioSciences (PCRX) in Q3 2021, closing a stake of 5,000 shares — an estimated $303K sold.

Tocqueville Asset Management first reported a position in PCRX in Q4 2014 and held it in 16 quarters. The position peaked at $1.36M in Q1 2015. 259 funds tracked by Wall St. Rank hold PCRX as of Q3 2021.

Tocqueville Asset Management reported no remaining Pacira BioSciences position as of Q3 2021 after selling out during the quarter.
Tocqueville Asset Management sold 5,000 Pacira BioSciences shares in Q3 2021, an estimated $303K.
Tocqueville Asset Management first reported a position in Pacira BioSciences in Q4 2014 and held it in 16 quarters.
Tocqueville Asset Management's Pacira BioSciences position peaked at $1.36M in Q1 2015.
259 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2021.

Based on Tocqueville Asset Management's 13F filing for Q3 2021, filed 15 Nov 2021.